To read the full story, subscribe or sign in.

Sofinnova Partners backs Naldini-led gene therapy startup

April 20, 2020

DUBLIN – Genespire Srl, a Milan-based startup led by gene therapy pioneer Luigi Naldini, is the third company to receive funding from Sofinnova Partners’ Italian €108 million (US$117.5 million) gene therapy fund, the Sofinnova Telethon Fund.

BioWorld Financings Gene therapy

Free access to BioWorld coronavirus articles

BioWorld

The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

Pfizer vaccine less effective against India variant of SARS-CoV-2

BioWorld

LONDON – A new U.K. study indicates the Pfizer Inc./Biontech SE COVID-19 vaccine is less effective against the India variant of the SARS-CoV-2 virus that was...

Novo to launch weekly weight loss drug Wegovy at same price as daily shot

BioWorld

Novo Nordisk A/S will this month launch its weekly weight loss glucagon-like peptide-1 injection Wegovy (semaglutide) at the same monthly cost as its older daily...

Today's news in brief

BioWorld

BioWorld briefs for June 23.

Innova hit with warning letter after FDA issues recall for COVID-19 test

BioWorld MedTech

The FDA issued a June 10 warning letter to Innova Medical Group Inc. in connection with the company’s rapid antigen tests for the SARS-CoV-2 virus, an action that...